FIG 2.
Intratracheal GH therapy does not induce pulmonary damage. Immunocompetent BALB/c mice were intratracheally administered a single dose of 250/250 μg PslGh-PelAh or PslGh-Ega3h. (A) Lactate dehydrogenase activity was quantified in BAL fluid. (B) Pulmonary leukocyte populations, including lymphocytes, macrophages, eosinophils, and neutrophils, were quantified by flow cytometry 7 days after GH treatment. Bars represent the means ± standard errors of 4 independent experiments with ≥13 mice per group. Asterisks indicate significant differences (P < 0.0020), relative to the buffer-treated group and where there are no asterisks no significant differences were observed as compared with the buffer-treated group (P > 0.7794), as determined by two-way ANOVA with Dunnett’s multiple-comparison test.